Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
PURPOSE: Current knowledge of the reasons for patients’ preference for rheumatoid arthritis (RA) treatment modes is limited. This study was designed to identify preferences for four treatment modes, and to obtain in-depth information on the reasons for these preferences. PATIENTS AND METHODS: In thi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980841/ https://www.ncbi.nlm.nih.gov/pubmed/32021123 http://dx.doi.org/10.2147/PPA.S220714 |
_version_ | 1783491001505021952 |
---|---|
author | Taylor, Peter C Betteridge, Neil Brown, T Michelle Woolcott, John Kivitz, Alan J Zerbini, Cristiano Whalley, Diane Olayinka-Amao, Oyebimpe Chen, Connie Dahl, Palle Ponce de Leon, Dario Gruben, David Fallon, Lara |
author_facet | Taylor, Peter C Betteridge, Neil Brown, T Michelle Woolcott, John Kivitz, Alan J Zerbini, Cristiano Whalley, Diane Olayinka-Amao, Oyebimpe Chen, Connie Dahl, Palle Ponce de Leon, Dario Gruben, David Fallon, Lara |
author_sort | Taylor, Peter C |
collection | PubMed |
description | PURPOSE: Current knowledge of the reasons for patients’ preference for rheumatoid arthritis (RA) treatment modes is limited. This study was designed to identify preferences for four treatment modes, and to obtain in-depth information on the reasons for these preferences. PATIENTS AND METHODS: In this multi-national, cross-sectional, qualitative study, in-depth interviews were conducted with adult patients with RA in the United States, France, Germany, Italy, Spain, Switzerland, the United Kingdom, and Brazil. Patients’ strength of preference was evaluated using a 100-point allocation task (0–100; 100=strongest) across four treatment modes: oral, self-injection, clinic-injection, and infusion. Qualitative descriptive analysis methods were used to identify, characterize, and summarize patterns found in the interview data relating to reasons for these preferences. RESULTS: 100 patients were interviewed (female, 75.0%; mean age, 53.9 years; mean 11.6 years since diagnosis). Among the four treatment modes, oral administration was allocated the highest mean (standard deviation) preference points (47.3 [33.1]) and was ranked first choice by the greatest percentage of patients (57.0%), followed by self-injection (29.7 [27.7]; 29.0%), infusion (15.4 [24.6]; 16.0%), and clinic-injection (7.5 [14.1]; 2.0%). Overall, 56.0% of patients had a “strong” first-choice preference (ie, point allocation ≥70); most of these patients chose oral (62.5%) vs self-injection (23.2%), infusion (10.7%), or clinic-injection (3.6%). Speed and/or ease of administration were the most commonly reported reasons for patients choosing oral (52.6%) or self-injection (55.2%). The most common reasons for patients not choosing oral or self-injection were not wanting to take another pill (37.2%) and avoiding pain due to needles (46.5%), respectively. CONCLUSION: These data report factors important to patients regarding preferences for RA treatment modes. Patients may benefit from discussions with their healthcare professionals and/or patient support groups, regarding RA treatment modes, to facilitate shared decision-making. |
format | Online Article Text |
id | pubmed-6980841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-69808412020-02-04 Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making Taylor, Peter C Betteridge, Neil Brown, T Michelle Woolcott, John Kivitz, Alan J Zerbini, Cristiano Whalley, Diane Olayinka-Amao, Oyebimpe Chen, Connie Dahl, Palle Ponce de Leon, Dario Gruben, David Fallon, Lara Patient Prefer Adherence Original Research PURPOSE: Current knowledge of the reasons for patients’ preference for rheumatoid arthritis (RA) treatment modes is limited. This study was designed to identify preferences for four treatment modes, and to obtain in-depth information on the reasons for these preferences. PATIENTS AND METHODS: In this multi-national, cross-sectional, qualitative study, in-depth interviews were conducted with adult patients with RA in the United States, France, Germany, Italy, Spain, Switzerland, the United Kingdom, and Brazil. Patients’ strength of preference was evaluated using a 100-point allocation task (0–100; 100=strongest) across four treatment modes: oral, self-injection, clinic-injection, and infusion. Qualitative descriptive analysis methods were used to identify, characterize, and summarize patterns found in the interview data relating to reasons for these preferences. RESULTS: 100 patients were interviewed (female, 75.0%; mean age, 53.9 years; mean 11.6 years since diagnosis). Among the four treatment modes, oral administration was allocated the highest mean (standard deviation) preference points (47.3 [33.1]) and was ranked first choice by the greatest percentage of patients (57.0%), followed by self-injection (29.7 [27.7]; 29.0%), infusion (15.4 [24.6]; 16.0%), and clinic-injection (7.5 [14.1]; 2.0%). Overall, 56.0% of patients had a “strong” first-choice preference (ie, point allocation ≥70); most of these patients chose oral (62.5%) vs self-injection (23.2%), infusion (10.7%), or clinic-injection (3.6%). Speed and/or ease of administration were the most commonly reported reasons for patients choosing oral (52.6%) or self-injection (55.2%). The most common reasons for patients not choosing oral or self-injection were not wanting to take another pill (37.2%) and avoiding pain due to needles (46.5%), respectively. CONCLUSION: These data report factors important to patients regarding preferences for RA treatment modes. Patients may benefit from discussions with their healthcare professionals and/or patient support groups, regarding RA treatment modes, to facilitate shared decision-making. Dove 2020-01-20 /pmc/articles/PMC6980841/ /pubmed/32021123 http://dx.doi.org/10.2147/PPA.S220714 Text en © 2020 Taylor et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Taylor, Peter C Betteridge, Neil Brown, T Michelle Woolcott, John Kivitz, Alan J Zerbini, Cristiano Whalley, Diane Olayinka-Amao, Oyebimpe Chen, Connie Dahl, Palle Ponce de Leon, Dario Gruben, David Fallon, Lara Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making |
title | Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making |
title_full | Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making |
title_fullStr | Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making |
title_full_unstemmed | Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making |
title_short | Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making |
title_sort | treatment mode preferences in rheumatoid arthritis: moving toward shared decision-making |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980841/ https://www.ncbi.nlm.nih.gov/pubmed/32021123 http://dx.doi.org/10.2147/PPA.S220714 |
work_keys_str_mv | AT taylorpeterc treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking AT betteridgeneil treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking AT browntmichelle treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking AT woolcottjohn treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking AT kivitzalanj treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking AT zerbinicristiano treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking AT whalleydiane treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking AT olayinkaamaooyebimpe treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking AT chenconnie treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking AT dahlpalle treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking AT poncedeleondario treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking AT grubendavid treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking AT fallonlara treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking |